Bin Yao

ORCID: 0000-0001-8639-9697
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diabetes Management and Research
  • Diabetes and associated disorders
  • Diabetes Treatment and Management
  • Pancreatic function and diabetes
  • Statistical Methods in Clinical Trials
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Esophageal Cancer Research and Treatment
  • Diabetes Management and Education
  • Metabolism, Diabetes, and Cancer
  • Gestational Diabetes Research and Management
  • Gastric Cancer Management and Outcomes
  • Cancer Treatment and Pharmacology
  • Neurological Disorders and Treatments
  • Cardiovascular Health and Risk Factors
  • Oral health in cancer treatment
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Diet and metabolism studies
  • Liver Disease Diagnosis and Treatment
  • Cancer, Hypoxia, and Metabolism
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • MicroRNA in disease regulation
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Advanced Causal Inference Techniques

Hebei Medical University
2025

Fourth Hospital of Hebei Medical University
2025

Nanjing University of Chinese Medicine
2023-2024

Third Affiliated Hospital of Sun Yat-sen University
2013-2024

Sun Yat-sen University
2009-2024

Huzhou University
2014-2024

Zhaoqing University
2024

Shijiazhuang Tiedao University
2024

Southeast University
2022-2023

Suzhou Traditional Chinese Medicine Hospital
2023

Miguel Martín Frankie A. Holmes Bent Ejlertsen Suzette Delaloge Beverly Moy and 95 more Hiroji Iwata Gϋnter von Minckwitz Stephen Chia Janine Mansi Carlos H. Barrios Michael Gnant Z. Tomasevic Neelima Denduluri Robert Šeparović Erhan Gökmen Anna Bashford Manuel Ruíz Borrego Sung‐Bae Kim Erik Jakobsen A. Ciceniene Kenichi Inoue Friedrich Overkamp Joan B. Heijns Anne Armstrong John S. Link Anil A. Joy Richard Bryce Alvin Wong Susan Moran Bin Yao Feng Xu Alan Auerbach Marc Buyse Arlene Chan Vernon Harvey Rudolf Tomek Nicholas J. Robert Ira Gore John W. Smith Norikazu Masuda S. Di Sean Kendall William Graydon Harker Katarína Petráková Ángel Guerrero‐Zotano Amparo Ruiz Simón Zora Neskovic Konstantinovic Nicholas Iannotti Pierfrancesco Tassone Gladys Rodriguez Noelia Jáñez Martínez Carmen Crespo Massieu Snezana Smickoska Işıl Somali Uğur Yılmaz Mirta Garcia Alonso Adolfo Rosales Soeren Cold Ann Knoop Debra A. Patt Beth A. Hellerstedt Serafín Morales Ingrid A. Mayer Julie A. Means‐Powell Rina Hui Francis M. Senecal Richard Hendry De Boer Zhenzhou Shen Adam Andrzej Luczak Joanna W.Y. Chui Janice Tsang István Láng Yoshiaki Rai Yasuo Hozumi Albert J. ten Tije Manish Bhandari Cynthia R. Osborne Shoichiro Ohtani Kenji Higaki Kenichi Watanabe Kazunori TAGUCHI Masato Takahashi Sladjana Filipovic Vincent Hansen Vijayarama Phooshkooru Rao Manish Gupta Petar Petrov Bruno Coudert Željko Vojnović Zsofia Polya Toshiko Miyaki Naohito Yamamoto Stephen Brincat Krzysztof Leśniewski-Kmak Ewa Chmielowska Ruemu Birhiray Marc L. Citron Steven W. Papish William L. Berry Sven Tyge Langkjer José A. García‐Sáenz

10.1016/s1470-2045(17)30717-9 article EN The Lancet Oncology 2017-11-14

NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, reversible dual TKI, (L+C) in patients with centrally confirmed HER2-positive, metastatic breast cancer (MBC) ≥ 2 previous HER2-directed MBC regimens.Patients, including those stable, asymptomatic CNS disease, were randomly assigned 1:1 to neratinib (240 mg once every day)...

10.1200/jco.20.00147 article EN cc-by-nc-nd Journal of Clinical Oncology 2020-07-17

To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add‐on liraglutide, sitagliptin, or insulin glargine this 26‐week trial. The primary endpoint was change intrahepatic lipid (IHL) from baseline week 26 as quantified magnetic resonance imaging–estimated proton density fat fraction (MRI‐PDFF). Secondary...

10.1002/hep.30320 article EN cc-by-nc-nd Hepatology 2018-10-20

OBJECTIVE—To investigate whether long-term optimal glycemic control can be achieved without medication by transient continuous subcutaneous insulin infusion (CSII) and the possible mechanisms responsible for this remission. RESEARCH DESIGN AND METHODS—Newly diagnosed type 2 diabetic patients (n = 138, fasting glucose >11.1mmol/l) were hospitalized treated with CSII weeks. Intravenous tolerance tests (IVGTTs) performed, blood glucose, HbA1c, lipid profiles, proinsulin, insulin,...

10.2337/diacare.27.11.2597 article EN Diabetes Care 2004-11-01

We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived receptor; Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients nonsquamous non-small-cell lung cancer (NSCLC) the subset adenocarcinoma.Patients stage IIIB/IV or recurrent NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under curve, 6 mg/ml ·...

10.1200/jco.2011.41.4987 article EN Journal of Clinical Oncology 2012-07-03

Abstract BACKGROUND: It has been reported that antidiabetic drugs affect the risk of cancer and prognosis patients with diabetes, but few studies have demonstrated influence different agents on outcomes after anticancer therapy among cancer. The objective this study was to evaluate metformin insulin advanced nonsmall cell lung (NSCLC) plus type 2 diabetes who received first‐line chemotherapy. METHODS: Data NSCLC had from 5 hospitals in China during January 2004 March 2009 were reviewed...

10.1002/cncr.26151 article EN Cancer 2011-04-26

Purpose: To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients metastatic colorectal cancer. Patients and Methods: (N = 81) received KGF by intravenous (IV) bolus on days 1 to 3, followed FU 425 mg/m 2 /d IV plus leucovorin 20 4 8. dose levels were 1, 10, 20, 40, 60, 80 μg/kg/d. A randomized, placebo-controlled design was employed (2:1 randomization placebo). Oral mucositis assessed examination 4, 8, 15, 28. In...

10.1200/jco.2003.10.079 article EN Journal of Clinical Oncology 2003-04-15

Monitoring patient safety during clinical trials is a critical component throughout the drug development life-cycle. Pharmaceutical sponsors must work proactively and collaboratively with all stakeholders to ensure systematic approach monitoring. The regulatory landscape has evolved increased requirements for risk management plans, evaluation minimization strategies. As industry transitions from passive active surveillance activities, there will be greater demand more comprehensive...

10.3390/pharmaceutics5010094 article EN cc-by Pharmaceutics 2013-01-17

Oogenesis is a fundamental process of human reproduction, and mitochondria play crucial roles in oocyte competence. Mitochondrial ATP-dependent Lon protease 1 (LONP1) functions as critical protein maintaining mitochondrial cellular homeostasis somatic cells. However, the essential role LONP1 mammalian oogenesis far from elucidated.Using conditional Lonp1-knockout mice, RNA sequencing (RNA-seq) coimmunoprecipitation/liquid chromatography-mass spectrometry (Co-IP/LC-MS) technology, we analysed...

10.1016/j.ebiom.2021.103790 article EN cc-by-nc-nd EBioMedicine 2021-12-30

We propose a group sequential Holm procedure when there are multiple primary endpoints. This method addresses multiplicities arising from endpoints and analyses in design. It has been shown to be closed testing preserves the familywise error rate strong sense. When only concern without an interim analysis, simplifies weighted procedure. The proposed is more powerful than parallel avoids need anticipate order as fixed sequence scheme.

10.1002/sim.5700 article EN Statistics in Medicine 2012-12-14

MicroRNA-613 (miR-613) plays important roles in tumorigenesis and cancer progression. We aimed to evaluate its expression level potential for diagnosis prognosis esophageal squamous cell (ESCC). examined miR-613 60 pairs of ESCC cancerous matched paracancerous tissues, serum samples from 75 patients healthy volunteers, 105 formalin-fixed paraffin-embedded (FFPE) tissue using quantitative reverse transcription polymerase chain reaction. Receiver-operating characteristic (ROC) curve analysis,...

10.1007/s13277-015-4271-8 article EN Tumor Biology 2015-10-24

Glycaemic control is a great challenge in the management of type 1 diabetes mellitus (T1DM). There limited data concerning glycaemic among adults with T1DM. We used from Guangdong T1DM Translational Medicine Study to evaluate and its associated factors Chinese T1DM.This cross-sectional analysis included 827 participants who were 18 years age or older had been living for at least year. Participants HbA1c levels <7% compared against those ≥ 7%. A multivariate logistic regression model was...

10.1002/dmrr.2716 article EN Diabetes/Metabolism Research and Reviews 2015-09-19

Adenovirus (Ad)-based antiangiogenesis gene therapy is a promising approach for cancer treatment. Downregulation or loss of coxsackievirus and adenovirus receptor (CAR) often detected in various human cancers, which hampers adenoviral approaches. Cationic liposome-complexed vectors have been proven useful CAR-deficient cells to enhance therapeutic transfer vivo. Here, we investigated the antitumor effects recombinant encoding endostatin (Ad-hE) encapsulated cationic liposome (Ad-hE/Lipo) on...

10.1089/hum.2011.014 article EN Human Gene Therapy 2011-05-26

LBA7512 Background: This study evaluated whether motesanib (a selective oral inhibitor of VEGFR 1, 2 and 3; PDGFR Kit) plus C/P improved overall survival (OS) compared with placebo + in patients (pts) nonsquamous NSCLC a subset pts adenocarcinoma. Methods: Pts had stage IIIB/IV or recurrent no prior systemic therapy for advanced NSCLC. The initially enrolled all histologies but was amended to exclude squamous owing high rate hemoptysis. were randomized 1:1 receive up six 3-wk cycles C (AUC 6...

10.1200/jco.2011.29.18_suppl.lba7512 article EN Journal of Clinical Oncology 2011-06-20

Abnormal paired box 9 (PAX9) expression is associated with tumorigenesis, cancer development, invasion and metastasis. The present study investigated the prognostic significance of PAX9 in esophageal squamous cell carcinoma (ESCC) its role predicting radiation sensitivity. A total 52.8% (121/229) ESCC tissues were positive for PAX9. 1‑, 3‑ 5‑year disease‑free survival (DFS) rates 72.2, 35.2 5.6%, respectively, overall (OS) 86.1, 44.4, 23.1%, PAX9‑positive tumors. In PAX9‑negative tumors,...

10.3892/mmr.2017.6626 article EN cc-by-nc-nd Molecular Medicine Reports 2017-01-01

Abstract Context New strategies and biomarkers are needed in the early detection of β-cell damage progress type 1 diabetes mellitus (T1DM). Objective To explore whether serum microRNAs (miRNA) should be served as for T1DM. Design, Settings, Patients The miRNA profile was established with microarray discovery phase (six T1DM, six controls). A miRNA-based model T1DM diagnosis developed using logistic regression analysis training dataset (40 56 controls) then validated leave-one-out cross...

10.1210/jc.2017-01417 article EN The Journal of Clinical Endocrinology & Metabolism 2018-01-23

Abstract Aims/hypothesis The study aimed to investigate the effects of HLA class I genes on susceptibility type 1 diabetes with different onset ages, in addition well-established II genes. Methods A total 361 patients (192 &lt;18 years and 169 ≥18 years) 500 healthy control participants from China were enrolled genotyped for HLA-A , -B -C -DQA1 -DQB1 -DRB1 using next-generation sequencing. Results susceptible DR3 (β = −0.09, p 0.0009) DR4-DQ8 −0.13, 0.0059) haplotypes negatively associated...

10.1007/s00125-021-05476-6 article EN cc-by Diabetologia 2021-05-22

Our aim was to investigate the impact of glycemic variability (GV) on relationship between glucose management indicator (GMI) and laboratory glycated hemoglobin A1c (HbA1c).Adult patients with type 1 diabetes mellitus (T1D) were enrolled from five hospitals in China. All subjects wore iPro™2 system for 14 days before HbA1c measured at baseline, 3 months 6 months. Data derived sensor used calculate GMI GV parameters [standard deviation (SD), coefficient variation (CV), mean amplitude...

10.1177/2042018820931664 article EN cc-by-nc Therapeutic Advances in Endocrinology and Metabolism 2020-01-01
Coming Soon ...